Log in

LON:HIKHikma Pharmaceuticals Share Price, Forecast & News

GBX 2,239
+20.00 (+0.90 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
2,207
Now: GBX 2,239
2,241
50-Day Range
2,220
MA: GBX 2,412.26
2,575
52-Week Range
1,596
Now: GBX 2,239
2,670
Volume1.43 million shs
Average Volume822,138 shs
Market Capitalization£5.16 billion
P/E Ratio11.20
Dividend Yield2.16%
BetaN/A
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals. The Generics segment develops and sells oral and other non-injectable generic products for retail market. The Branded segment develops, manufactures, and markets branded generics and in-licensed products to retail and hospital markets. The company offers products in various therapeutic areas, including respiratory, oncology, pain management, anti-infectives, cardiovascular, diabetes, and central nervous system. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Read More
Hikma Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.2Community Rank: 2.8Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.38 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-73992760

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£2.21 billion
Cash FlowGBX 191.90 per share
Book ValueGBX 873.80 per share

Profitability

Miscellaneous

Employees8,400
Market Cap£5.16 billion
Next Earnings Date8/7/2020 (Estimated)
OptionableNot Optionable

Receive HIK News and Ratings via Email

Sign-up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter.

Hikma Pharmaceuticals (LON:HIK) Frequently Asked Questions

How has Hikma Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Hikma Pharmaceuticals' stock was trading at GBX 1,828.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HIK stock has increased by 22.5% and is now trading at GBX 2,239. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Hikma Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Hikma Pharmaceuticals.

When is Hikma Pharmaceuticals' next earnings date?

Hikma Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 7th 2020. View our earnings forecast for Hikma Pharmaceuticals.

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals declared a dividend on Thursday, February 27th. Shareholders of record on Thursday, March 19th will be given a dividend of GBX 0.30 per share on Thursday, May 7th. This represents a dividend yield of 1.22%. The ex-dividend date is Thursday, March 19th. This is an increase from Hikma Pharmaceuticals's previous dividend of GBX 0.14. The official announcement can be accessed at this link. View Hikma Pharmaceuticals' dividend history.

What price target have analysts set for HIK?

8 brokerages have issued 12-month target prices for Hikma Pharmaceuticals' shares. Their forecasts range from GBX 2,200 to GBX 2,500. On average, they expect Hikma Pharmaceuticals' stock price to reach GBX 2,378.33 in the next twelve months. This suggests a possible upside of 6.2% from the stock's current price. View analysts' price targets for Hikma Pharmaceuticals.

Has Hikma Pharmaceuticals been receiving favorable news coverage?

News headlines about HIK stock have been trending somewhat positive on Friday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Hikma Pharmaceuticals earned a coverage optimism score of 1.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news about Hikma Pharmaceuticals.

Who are some of Hikma Pharmaceuticals' key competitors?

What other stocks do shareholders of Hikma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Gran Tierra Energy (GTE), Och-Ziff Capital Management Group (OZM) and Belden (BDC).

Who are Hikma Pharmaceuticals' key executives?

Hikma Pharmaceuticals' management team includes the following people:
  • Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 62)
  • Mr. Mazen Samih Taleb Darwazah, Exec. Vice Chairman & Pres of MENA (Age 61)
  • Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 50)
  • Mr. Khalid Walid Hussni Nabilsi, Chief Financial Officer (Age 47)
  • Dr. Surendera Tyagi, Group Chief Scientific Officer and Global Head of R&D

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

How do I buy shares of Hikma Pharmaceuticals?

Shares of HIK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Hikma Pharmaceuticals' stock price today?

One share of HIK stock can currently be purchased for approximately GBX 2,239.

How big of a company is Hikma Pharmaceuticals?

Hikma Pharmaceuticals has a market capitalization of £5.16 billion and generates £2.21 billion in revenue each year. Hikma Pharmaceuticals employs 8,400 workers across the globe.

What is Hikma Pharmaceuticals' official website?

The official website for Hikma Pharmaceuticals is www.hikma.com.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760.

This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.